BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawaguchi-suzuki M, Frye RF. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. Pharmacotherapy 2014;34:185-201. [DOI: 10.1002/phar.1349] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Gauthiez E, Habfast-robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Heim MH, Malinverni R, Moradpour D, Müllhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P; the Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. Liver Int 2017;37:1431-45. [DOI: 10.1111/liv.13401] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
2 D'Avolio A, Cusato J, De Nicolò A, Allegra S, Di Perri G. Pharmacogenetics of ribavirin-induced anemia in HCV patients. Pharmacogenomics 2016;17:925-41. [PMID: 27248282 DOI: 10.2217/pgs.16.22] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
3 Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
4 Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD. Recent advances in management of the HIV/HCV coinfected patient. Future Virol 2015;10:981-97. [PMID: 26877758 DOI: 10.2217/fvl.15.64] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
5 Schuck RN, Florian J, Charlab R, Pacanowski M. Trial geography, pharmacogenetics, and global drug development. Clin Pharmacol Ther 2015;97:218-20. [PMID: 25669642 DOI: 10.1002/cpt.27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Cusato J, Allegra S, De Nicolò A, Boglione L, Fatiguso G, Cariti G, Ciancio A, Smedile A, Strona S, Troshina G, Rizzetto M, Di Perri G, D'Avolio A. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. Biomed Pharmacother 2015;69:63-9. [PMID: 25661339 DOI: 10.1016/j.biopha.2014.11.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
7 Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, Dong BJ, GI Liver Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy 2014;34:1341-54. [PMID: 25359244 DOI: 10.1002/phar.1512] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
8 Pradat P, Virlogeux V, Gagnieu M, Zoulim F, Bailly F. Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring. Advances in Hepatology 2014;2014:1-13. [DOI: 10.1155/2014/493087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]